Description
NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes. By at least one estimate, approximately 6-8 million people in the U.S. have NASH with moderate to advanced liver scarring, with that number expected to increase. Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation.
Resmetirom is indicated, in conjunction with diet and exercise, for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)
The most common side effects include diarrhea and nausea.
Resmetirom was approved for medical use in the United States in March 2024, and in the European Union in August 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
REZDIFFRA (resmetirom) tablets, for oral use Initial U.S. Approval: 2024
See full prescribing information: Click Here
Contact Sourcing Facilitation Team
Contact Name: Mr. Tarun Garg
Address: 60/4, Yusaf Sarai, Near Indian Oil Corp., New Delhi – 110 016 (India)
Mobile/WhatsApp. 9891296838.
Email: support@southdelhipharma.com, southdelhipharma@gmail.com
Get Access Rezdiffra (resmetirom) In India on request.
Rezdiffra may be imported for personal treatment under the Named Patient Program (NPP) across India, including Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Aurangabad, Pune, Bengaluru, Hyderabad, Chennai, Visakhapatnam, Coimbatore, and other regions of India.
Note: South Delhi Pharma, act as a facilitation partner and do not manufacture, sell, or distribute pharmaceutical products. All facilitation activities are conducted in accordance with applicable Indian pharmaceutical and trade regulations.
